Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652002 | 0.81 | RET (0.50) | CHRM2CHRM1CHRM3HRH3RET | |
| SCHEMBL20147374 | 0.79 | HRH3 (0.41) | CHRM2CHRM1CHRM3HRH3CHRM4 | |
| SCHEMBL20147320 | 0.78 | SETD7 (0.36) | HRH3RETNR1H2 | |
| SCHEMBL18390342 | 0.78 | CHRM2 (0.54) | CHRM2CHRM1CHRM3HRH3PREP | |
| SCHEMBL20147344 | 0.75 | RET (0.34) | HRH3RET | |
| SCHEMBL20147346 | 0.74 | HRH3 (0.39) | HRH3RETNR1H2HSD11B1EPHX2 | |
| SCHEMBL20071158 | 0.72 | CHRM2 (0.54) | CHRM2CHRM1CHRM3PREPNR1H2 | |
| SCHEMBL20070270 | 0.71 | RET (0.51) | CHRM2CHRM1CHRM3RETCCR2 | |
| SCHEMBL20349493 | 0.71 | CHRM2 (0.49) | CHRM2CHRM1CHRM3RETPREP | |
| SCHEMBL20154542 | 0.70 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CHRM2 2821/4885CHRM1 2035/4885CHRM3 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.